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Abstract
Rationale: Hemolysis occurs not only in conditions such as sickle
cell disease and malaria but also during transfusion of stored blood,
extracorporeal circulation, and sepsis. Cell-free Hb depletes nitric
oxide (NO) in the vasculature, causing vasoconstriction and
eventually cardiovascular complications. We hypothesize that
Hb-binding proteins may preserve vascular NO signaling during
hemolysis.
Objectives: Characterization of an archetypical function by which
Hb scavenger proteins could preserve NO signaling during
hemolysis.
Methods:We investigated NO reaction kinetics, effects on arterial
NO signaling, and tissue distribution of cell-freeHb and its scavenger
protein complexes.
Measurements and Main Results: Extravascular translocation
of cell-free Hb into interstitial spaces, including the vascular
smoothmuscle cell layer of rat and pig coronary arteries, promotes
vascular NO resistance. This critical disease process is blocked
by haptoglobin. Haptoglobin does not change NO dioxygenation
rates of Hb; rather, the large size of the Hb:haptoglobin
complex prevents Hb extravasation, which uncouples
NO/Hb interaction and vasoconstriction. Size-selective
compartmentalization of Hb functions as a substitute for red
blood cells after hemolysis and preserves NO signaling in the
vasculature. We found that evolutionarily and structurally
unrelated Hb-binding proteins, such as PIT54 found in avian
species, functionally converged with haptoglobin to protect
NO signaling by sequestering cell-free Hb in large protein
complexes.
Conclusions: Sequential compartmentalization of Hb by
erythrocytes and scavenger protein complexes is an archetypical
mechanism,whichmayhave supported coevolutionof hemolysis and
normal vascular function. Therapeutic supplementation of Hb
scavengers may restore vascular NO signaling and attenuate disease
complications in patients with hemolysis.
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The red blood cell (RBC) pool of an adult
human contains more than 500 g Hb.
The broad reactivity of Hb necessitates
stringent control of its biochemistry to avoid
adverse physiological effects (1, 2). In
healthy individuals, this control is provided
by the compartmentalization of Hb within
RBCs. However, in patients with hemolysis
such as in sickle cell disease (SCD), during
extracorporeal circulation, on transfusion
of stored blood, or during malaria and
sepsis, substantial quantities of cell-free Hb
are occasionally released into plasma (3).
In these conditions, cell-free Hb can
promote disease complications (4–11).
Some of the most severe adverse effects
associated with cell-free Hb exposure,
including pulmonary and systemic
hypertension, are caused by depletion of the
vasodilator nitric oxide (NO) (12–16).
The toxicity of cell-free Hb and the
diversity of hemolytic conditions exerted an
evolutionary pressure that led to the
development of protective systems. In most
species haptoglobin (Hp) is the principal
Hb scavenger protein in plasma (17, 18).
Hp binds Hb ab-dimers within Hb:Hp
complexes, which are cleared from the
blood by liver and spleen macrophages
(19, 20). Hp inhibits Hb-triggered protein
and lipid oxidation, whereas the large size
of the Hb:Hp complex prevents renal Hb
excretion and kidney injury (6, 21, 22).
However, the most intriguing and presently
unexplained protective function of Hp is
its ability to attenuate hypertension that
is triggered by cell-free Hb (6, 23–25).
Because the NO reaction rates are comparable
for Hb and the Hb:Hp complex (23, 26),
we hypothesize that the large Hb:Hp
complex may shield vascular NO by
limiting cell-free Hb decompartmentalization
from the vascular lumen to the sites of
vascular NO activity.
An independent line of Hb-binding
proteins evolved over time to exploit the
ancient scavenger receptor cysteine-rich
(SRCR) domain as a scaffold (17). More
than 1,000 different SRCR domains provide
molecular pattern recognition and ligand-
binding functions in the innate immune
systems of primitive species, such as the sea
urchin (27, 28). In vertebrates, a more
restricted set of SRCR domain proteins
has acquired more specialized functions.
Among these proteins, the acute-phase
inducible plasma protein PIT54, which is
composed of four repetitive SRCR domains,
has been identiﬁed as an Hb-binding
protein in birds (17, 29). Thus far, the
protective functions of PIT54 have not
been characterized. Nonetheless, its existence
suggests that the toxicity of cell-free Hb
may have driven independent evolution of
redundant and structurally diverse Hb
scavenger systems with overlapping
functions.
In the current studies, we demonstrate
that Hb binding by Hp restores vascular
NO signaling during hemolysis, and we
deﬁne a shared function of the structurally
and evolutionarily unrelated Hb-binding
protein PIT54. Collectively, our data
illuminate an archetypical mechanism
that may have supported coevolution of
hemolysis and the vascular system and that
may provide therapeutic options to restore
NO signaling in patients with hemolysis.
Methods
Haptoglobin from human plasma
(phenotype 2-2 predominant) was
obtained from CSL Behring (Bern,
Switzerland). The identity, purity, and
function of the protein were conﬁrmed
by liquid chromatography–tandem mass
spectrometry (LC-MS/MS), polyacrylamide
gel electrophoresis, and surface plasmon
resonance as described (24). Hemoglobin
was puriﬁed from outdated blood, as
previously described (24). Hb concentrations
were determined by spectrophotometry
and are given as molar concentration of
total heme (1 M Hb tetramer is therefore
equivalent to 4 M heme). For all Hb used in
these studies, the fraction of ferrous HbO2
was always greater than 98%, as determined
by spectrophotometry, unless stated
otherwise. Recombinant PIT54 was
expressed in HEK293 cells.
A detailed description of the materials
and methods is included in the online
supplement.
Results
Hp Enhances the NO Vasodilator
Reserve during Intravascular Hb
Exposure in Rats
Rats were infused with 35 mg of HbO2
(n = 4) or HbO2 bound to Hp (n = 4). In the
ﬁrst 10 minutes after infusion, the mean
arterial pressure (MAP) increased more
than 10% with Hb treatment but only 2.5%
after infusion with Hb bound to Hp
(Figure 1A). After 10 minutes, a single
5-mg bolus dose of the endothelial NO
synthase (eNOS) inhibitor L-NG-
nitroarginine methyl ester (L-NAME) was
administered. L-NAME increased MAP by
57 and 92% compared with the mean values
after infusion with Hb and Hb:Hp,
respectively (Figure 1B). The stronger MAP
increase after L-NAME treatment of
Hb:Hp–infused rats suggested that Hp
preserved NO function in Hb-infused
animals.
In a second model, acetylcholine (ACh)
was infused into rats to maximize eNOS
activity. Over 5 minutes of ACh infusion the
MAP was reduced by approximately 40%
(see Figure E1 in the online supplement).
Under these conditions, a dose of 35 mg of
cell-free Hb or Hb bound to Hp slightly
increased MAP without a signiﬁcant
difference between the two groups. In both
groups, MAP clearly persisted below
baseline levels. However, on cessation of the
ACh infusion, free Hb–exposed animals
demonstrated a MAP increase to 30%
greater than baseline, whereas Hb:Hp-
exposed animals demonstrated only a 5%
overshoot of basal mean values (P, 0.01).
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Diseases and medical
interventions leading to acute and
chronic hemolysis can cause
vasoconstriction, hypertension,
and eventually cardiovascular
complications resulting from nitric
oxide (NO) depletion by cell-free Hb.
What This Study Adds to the
Field: This study demonstrates that
extravasation of cell-free Hb into
perivascular sites is a critical disease
process resulting in Hb-induced
vascular NO resistance and
vasoconstriction. Hb
compartmentalization within the
vascular lumen by the plasma protein
haptoglobin or by a structurally
unrelated evolutionary decedent Hb-
binding protein, PIT54, prevents
extravasation and vasoconstriction.
This NO-preserving function of
haptoglobin suggests a therapeutic
potential for vascular protection during
active hemolysis.
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Figure 1. Haptoglobin (Hp) enhances nitric oxide (NO)-mediated arterial dilation during Hb exposure. (A, left panel) Change in mean arterial blood
pressure (MAP) of rats after injection of 35 mg cell-free Hb with or without Hp. Data show the mean6 SEM, n = 4. (A, right panel) Comparison of maximum
MAP changes (*P, 0.01). (B, left panel) Ten minutes after the initial Hb6Hp injection, the animals were treated with L-NG-nitroarginine methyl ester
(L-NAME), and MAP was monitored for a further 20 minutes to estimate the “NO reserve.” (B, right panel) Comparison of maximum L-NAME–induced
changes in MAP in Hb6Hp-pretreated rats (*P, 0.01). (C) Relative contractile response of porcine coronary arteries pretreated with prostaglandin
F2a (PGF2a) (6N5-[1-iminoethyl]-L-ornithine [L-NIO]) in response to a range of concentrations of Hb or Hb:Hp complexes (mean6 SEM of n = 11–15
vascular rings) (*P, 0.001). (D, E) PGF2a precontracted porcine coronary arteries were dilated with either the intracellular NO donor nitroglycerin (NTG)
(D) or the extracellular NO donor DETA-NONOate (DETA) (E). Each NO donor was applied at two different concentrations, and the contractile response to
various concentrations of Hb and Hb:Hp was measured (mean6 SEM of n = 15 vascular rings) (*P , 0.001). (F) Relative contraction of PGF2a
precontracted and nitroglycerin (10 mM)-dilated porcine coronary arteries in response to a range of concentrations of ferrous HbO2 (Fe
21) or ferric Hb
(Fe31) (mean6 SEM of n = 24 and 9 vascular rings for ferrous and ferric Hb, respectively) (*P , 0.001). (G) Original tension traces of three arterial rings
(prepared from different porcine hearts) from an experiment as shown in D–F. At the end of the Hb dose response, albumin or Hp were added at a
concentration of 32 mM. Black arrows mark the serial addition of the indicated compounds in half-log10 steps. For all arterial ring tension experiments, the
baseline tension before PGF2a treatment is considered 0%, and the tension at maximum PGF2a response is considered 100%. Responses are therefore
indicated as % PGF2a. n.s. = not significant.
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These data suggest that maximal
endogenous NO production could reverse
the hypertensive effect of cell-free Hb but
that Hp is critical to preserve vasodilator
NO signaling under physiologic conditions.
Hp Blocks the Vasoconstrictor
Activity of Hb in NO-dilated Porcine
Coronary Arteries
Next, we studied the effects of HbO2 and
HbO2 plus Hp on vascular tone in porcine
coronary arteries ex vivo. In a ﬁrst set of
experiments, coronary artery rings were
precontracted with prostaglandin F2a
(PGF2a). The precontracted arteries were
subsequently exposed to increasing
concentrations of Hb (Figure 1C, red
symbols) or Hb:Hp (Figure 1C, white
symbols) in the absence or presence of the
eNOS inhibitor N5-(1-iminoethyl)-L-
ornithine (L-NIO). Free Hb, but not Hb:Hp,
caused dose-dependent contractions of the
arteries. When endogenous NO was
depleted before Hb exposure by
pretreatment with L-NIO, the additional
contraction induced by cell-free Hb was
signiﬁcantly attenuated. These ﬁndings
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Figure 2. Haptoglobin (Hp) uncouples nitric oxide (NO) depletion in solution and NO–cyclic guanosine
39,59-monophosphate (cGMP) signaling function in the vascular wall during Hb exposure. (A) An example of
a stopped-flow experiment of the reaction of HbO26Hp with NO. The traces show the normalized
absorption changes at 406 nm (red: free Hb; blue: Hb:Hp complex), with HbO2 in excess at pH 7.4. (B) NO
depletion after injection with either Hb or Hb:Hp into an air-tight, oxygen-free reaction chamber in which NO
was continuously produced by DETA-NONOate decay in phosphate-buffered saline (pH 7.4). NO was
measured online in the carrier gas phase with an ANTEK chemiluminescence NO detector. Depletion by Hb
Figure 2. (Continued). was set at 100%
and was not statistically different from depletion by
Hb:Hp. (C) The NO-mediated dilatory response of
prostaglandin F2a (PGF2a) precontracted porcine
coronary artery segments was measured after in-
jection of MAHMA-NONOate boluses (30 nM)
into the immersion buffer. Experiments were
performed in buffer only, with Hb (32 mM) or with
Hb:Hp (32 mM). The traces show mean6 SEM of
at least 15 averaged responses recorded in
three independent experiments. In parallel to the
vascular response, the NO concentration was
measured in vessel immersion buffer using an
NO-sensitive microelectrode. The red arrows indi-
cate addition of NO donor. (D) MAHMA-NONOate
induced vascular dilation in the presence of intact
red blood cells (RBCs) (32 mMHb). No dilation was
observed after lysis of RBCs (32 mM Hb) or
with intact RBCs in the presence of the guanylate-
cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]
quinoxalin-1-one (ODQ) (10 mM). The experiment
was identical to that in C. Red arrow indicates the
time point of MAHMA-NONOate injection. (E)
MAHMA-NONOate induced vascular dilation
in the presence of lysed RBCs (32 mM Hb)1Hp.
The cGMP inhibitors ODQ (10 mM) and NS2028
(10 mM) blocked the NO dilatory response. The
experiment was identical to that in C. The red arrow
indicates the time point of MAHMA-NONOate in-
jection. Traces in D and E represent mean6 SEM
of at least 15 averaged responses recorded in three
independent experiments. n.s. = not significant.
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suggest that Hp may preserve dilatory
signaling of endogenous NO during cell-
free Hb exposure.
To directly explore the potential
NO-preserving function of Hp, we
examined the effects of Hb and Hb:Hp
on arteries that were precontracted with
PGF2a and subsequently dilated to baseline
tension with exogenous NO derived from
chemical NO donors. We used either the
intracellular NO donor nitroglycerin or the
extracellular NO donor DETA-NONOate.
The cell-free Hb–mediated contraction of
the NO-dilated arteries was dose dependent
and inversely correlated with the level of
NO generated by different NO donor
concentrations (Figures 1D and 1E, red
symbols). This result indicates that the
Hb-induced contraction in our system is
a direct result of the stoichiometric
consumption of NO by HbO2, which only
occurs with NO-reactive ferrous HbO2
(Fe21) but not ferric Hb (Fe31) (Figure 1F).
The addition of Hp almost completely
blocked the Hb-mediated contractile
response (white symbols). Furthermore,
addition of Hp, but not addition of
albumin, rapidly and fully reverted the
Hb-induced contraction (Figure 1G). In
an Hb-free system, Hp had no dilatory
activity on PGF2a precontracted arteries
(data not shown).
Hp Uncouples NO/Hb Interaction and
Vasoconstriction
Earlier studies have suggested that Hp does
not affect the NO dioxygenation reaction
of bound Hb (23, 26). To assess the validity
of these observations in our system, we
measured the dioxygenation kinetics of free
HbO2 and HbO2:Hp complexes with NO
by stopped-ﬂow spectroscopy under
pseudo–ﬁrst-order conditions (Figure 2A).
Averaged kinetic traces measured at 406
nm were ﬁtted to an exponential curve with
a second-order rate constant of 79.26
4 mM21 $ s21 and 66.76 6 mM21 $ s21 for
free Hb and Hb:Hp, respectively (means of
eight experiments). Our rate constant for
free Hb is comparable to those previously
published (15, 30). When we directly
measured the NO consumption by cell-free
HbO2 and the Hb:Hp complex with a
chemiluminescence NO analyzer, we found
no statistically signiﬁcant differences
(Figure 2B). This ﬁnding suggests that,
despite the slightly lower rate constant of
the Hb:Hp complex, the two compounds
may equally deplete NO in a physiologic
system. The assumption that the small
(15%) difference in the reaction rates of Hb
and the Hb:Hp complex could not explain
the drastically reduced vasoconstrictor
activity of the complex is also in agreement
with ﬁndings reported in previous studies
of heme-pocket mutated Hbs, which
demonstrated that a greater reduction of
the NO dioxygenation rate is necessary to
signiﬁcantly reduce vasopressor activity
in vivo (31).
In the next set of experiments, we
measured (in parallel) the vasodilatory activity
of an NO donor and the accumulation of
NO in the buffer solution. For this experiment
an NO-sensitive electrode was placed in
proximity (1 mm) to the monitored artery
segments. NO was generated in situ after
injection of the short-lived NO donor
MAHMA-NONOate into the buffer solution.
In the absence of Hb, repeated addition of
MAHMA-NONOate caused bursts of NO
accumulation in the buffer, which were
accompanied by transient vascular dilations
(Figure 2C, left panel). When Hb (32 mM)
was added, no accumulation of NO and no
vascular dilation were observed after addition
of MAHMA-NONOate (Figure 2C, middle
panel). In the presence of the Hb:Hp
complex (32 mM), NO accumulation was still
not detectable after addition of the NO
donor. However, despite complete NO
consumption in the buffer, a strong
vasodilator response could be recorded in
arteries exposed to Hb:Hp. This response was
similar to the MAHMA-NONOate–induced
vasodilator response observed in the control
experiments. Hp also reverted Hb-induced
NO resistance of dog coronary arteries, which
were used in some experiments to conﬁrm
that the observed effects were not restricted to
certain animal species (Figure E2).
These ﬁndings suggest that Hp uncouples
the reaction of cell-free Hb-mediated NO
consumption in solution from additional
processes that are required to cause vascular
NO resistance.
Hp Substitutes an RBC Function to
Preserve Vasodilator NO–Cyclic
Guanosine 39,59-Monophosphate
Signaling during Hemolysis
MAHMA-NONOate–inducible vascular
dilations could also be induced in the
presence of intact RBCs (Figure 2D). These
dilations were blocked by the cyclic guanosine
3ʹ,5ʹ-monophosphate (cGMP) inhibitor
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
(ODQ) (10 mM). Although lysis of the RBCs
induced complete NO resistance
(Figure 2D), addition of Hp to the lysed
RBCs restored the vasodilator response
(Figure 2E). This experiment illustrates that
Hp can substitute an essential NO-sparing
function of RBCs during hemolysis. The
vasodilator response in the presence of
the Hb:Hp complex could also be blocked
by the guanylate cyclase inhibitors ODQ
(10 mM) and NS2028 (10 mM), suggesting
that Hp preserved the classic NO-cGMP
signaling pathway in the presence of
cell-free Hb.
Formation of a Large Protein
Complex Determines Vascular NO
Preservation by Hp
We hypothesized that the ability of Hp to
restore vascular NO signaling during
cell-free Hb exposure could be related to
the large molecular size of the complex,
which may restrict access of free Hb to
vascular smooth muscle cells. Moreover,
we postulated that the large size of the
Hb:Hp complex would be the principal
determinant of vascular NO protection.
To further explore this hypothesis, we
attempted to mimic an Hp-like activity by
conjugating Hb and albumin with chemical
groups that rapidly and selectively react
(“click”) with each other in the tetrazine-
trans-cyclooctene (TCO) ligation reaction
to form covalent crosslinks between the
two proteins (32, 33). In this chemical
reaction system, the functionalized albumin
should mimic the role of Hp as an Hb
scavenger without exhibiting any of the
Hp-typical structural features. The reaction
of TCO-functionalized Hb with tetrazine-
functionalized albumin resulted in large
crosslinking products, which retained
NO-depleting activity in solution (Figure E3).
PGF2a-precontracted and NO-dilated
porcine coronary arteries contracted
equally after exposure to either unmodiﬁed
Hb or Hb-TCO. However, when tetrazine-
functionalized albumin was added to the
Hb-TCO–exposed (contracted) arteries, the
vessels dilated, indicating that NO signaling
was restored. This dilation was comparable
to that observed when Hp was added to
bind cell-free Hb (Figure 3B). No dilation
occurred if either Hb or albumin was not
click-functionalized (Figure 3A).
To further support the role of a size-
selective mechanism, we compared the
effects of free Hb and theHb:Hp complex with
the vasoactivity of glutaraldehyde-polymerized
Hbs ranging in molecular size from 8 to
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25 nm (Figure 3C). These experiments
revealed that the molecular sizes of the
different Hb molecules negatively correlated
with the constrictive response (Figure 3D and
Table E1). In an analysis of variance model,
which considered molecular size, NO reaction
rates, and T- versus R-state conformation of
free Hb, the Hb:Hp complex, and all tested
polymerized Hbs as variables, only the
molecular size was found to signiﬁcantly
contribute to the variation in vascular
contraction that was induced by the different
compounds (Table E2).
Hp Blocks Hb Translocation into
Interstitial Tissue Spaces
Our functional studies support the
hypothesis that sequestration of cell-free
Hb in large protein complexes could
prevent cell-free Hb distribution to
tissue compartments of NO production
and/or activity. Therefore, to test this
hypothesis, we infused anesthetized rats
with Hb-TCO to achieve an intravascular
Hb exposure of 50 mM Hb over 60
minutes. Hb-positive tissue regions were
visualized by “click” reaction with
Cy5-tetrazine. The covalent and site-
speciﬁc conjugation reaction between
Hb-TCO and Cy5-tetrazine supported
speciﬁc and sensitive detection of Hb in
tissues. We tested this labeling strategy in
kidney sections (Figure 4A). No Cy5
signal was detected in control tissues or in
tissues obtained from animals perfused
with Hb that was functionalized with
another tag (Hb-azide) unable to
react with tetrazine. In contrast, the
Cy5-tetrazine reaction in renal tissue
from Hb-TCO–perfused animals
exhibited a strong ﬂuorescence signal
(red) in the renal cortical region. Hb
accumulation was markedly reduced
when Hp was added to the Hb-TCO
perfusion.
In the myocardium of Hb-TCO–infused
and Hp-treated animals, we found strong
Cy5 ﬂuorescence (red-yellow) conﬁned to
the lumen of small capillaries (Figure 4B,
lower image). However, in the absence of
Hp, a very strong Cy5 signal could be
observed in the interstitial spaces around
cardiomyocytes (Figure 4B, upper image).
This ﬁnding reﬂected extravasation of cell-
free Hb, which occurred only in the absence
of Hp. Similar Hb distribution was also
detected in muscular coronary arteries. In the
absence of Hp, a strong signal was detected in
the interstitial regions throughout the
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Figure 3. Large molecular-sized protein complex formation restores dilatory nitric oxide (NO)
signaling during Hb exposure. (A) Dilatory response after in situ polymerization of Hb. The plot shows
the dilatory response of porcine coronary arteries that were sequentially pretreated with prostaglandin
F2a (PGF2a), nitroglycerin (NTG), and Hb, resulting in an Hb-mediated constricted state. At this point
(time = 0 s) the albumin component was added. Hb polymerization and dilation were only observed
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vascular smooth muscle layer. Extremely
weak Cy5-Hb-TCO signal was detected in
Hb-TCO–perfused animals treated with Hp
(Figure 5).
We also examined whether Hb may
distribute into the tissues associated with
porcine coronary arteries. Hearts were
perfused ex vivo through the left main
coronary artery with cell-free Hb in the
absence or presence of Hp for 1 hour. The
photograph in Figure 6A shows left main
coronary artery segments (n = 4 per group)
placed in glass tubes with the endothelial
layer facing the glass surface (“inside-out”).
The discriminating brownish color, which
was most intense in the arteries from
Hb-perfused hearts, suggested extravasation
of Hb into the vascular wall. Accumulation
of Hb was not evident in Hb:Hp–perfused or
control hearts.
Next, we perfused hearts with Hb-TCO
with or without Hp. Figure 6B shows a
gel analysis of coronary artery lysates that
were reacted with Cy5-tetrazine before
gel separation. The Cy5-signal (yellow)
that associated speciﬁcally with the Hb
monomer at 15 kD was signiﬁcantly
more intense in samples obtained from
Hb-TCO–perfused hearts than in control
or Hb-TCO1Hp–perfused hearts. A
comparably decreased Hb accumulation
was observed when porcine hearts were
perfused with large molecular weight
polymerized Hbs (Figure E4). Hb-TCO
was also visualized by reaction of tissue
sections with Cy5-tetrazine (Figure 6C).
Hb-TCO was found in the muscular layer
of the large pericardial coronary arteries.
The area-normalized Cy5 signal was
quantiﬁed in the region between the
internal and external elastic membranes by
a blinded investigator. A signiﬁcantly
greater quantity of Hb accumulated in the
smooth muscle layer of coronary arteries
from Hb-TCO–perfused hearts compared
with that in Hb-TCO1Hp–perfused
hearts (Figure 6D).
Finally, Figure 6E shows representative
electron paramagnetic resonance (EPR)
spectra that were recorded at 6 K from
samples shown in Figure 6A. A clear
ferric heme-iron signal around g = 6,
which was more intense in Hb-perfused
arteries relative to that pertaining to
control or Hb:Hp–perfused arteries, was
detected. The concentration estimate of
the ferric high-spin heme in the vascular
wall was approximately 6 mM, which
corresponds to 3% of the perfusate Hb
concentration. Although this suggests that
a fraction of the ferrous HbO2 in the
perfusate is ultimately oxidized to ferric
Hb in the vascular wall, we cannot
calculate the total amount of Hb
translocated into the arterial wall by
this method because ferrous Hb is EPR
silent.
Hb Sequestration and Protection of
Vascular NO Signaling by PIT54
To support the assertion that Hb
sequestration in large protein complexes
could be a very fundamental and
evolutionarily redundant mechanism to
prevent cell-free Hb–induced vascular NO
resistance, we examined whether the
SRCR Hb-binding protein PIT54 shared
the NO-shielding mechanism of Hp
(Figure 7A). Surface plasmon resonance
experiments demonstrated that chicken
Hb (cHb), but not human Hb, binds to
recombinant PIT54 with a high afﬁnity
(Kd = 0.37 mM), although it did not show
the irreversible complex formation that can
be observed with Hp (Figure 7B). Size
exclusion chromatography demonstrated
that a stable, large cHb-PIT54 complex was
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formed under physiological conditions
(Figure 7C). As with the Hb:Hp complex,
PIT54 complex formation only minimally
reduced the NO reaction rate of cHb
(Figure 7D). The NO dioxygenation rate
constant for cHbO2 of 81.66 0.1 mM
21 $ s21
is almost identical to the rate of human
HbO2. The NO dioxygenation rate constant
of the cHbO2:PIT54 complex was
66.96 5 mM21 $ s21.
cHbO2 at 10 mM completely
suppressed the NO-dependent dilation of
porcine coronary artery segments, which
was induced by injection of MAHMA-
NONOate into the buffer solution.
Analogous to the effect of Hp, addition of
15 mM PIT54 restored NO sensitivity
almost to the extent observed in control
experiments (Figures 7E and 7F).
The cGMP inhibitor ODQ could block the
dilatory response that occurred in the
presence of the cHb-PIT54 complexes.
Discussion
Our ﬁndings support the hypothesis that
extravasation of cell-free Hb is a critical
disease process in hemolysis, which
ultimately leads to interference of Hb with
vascular NO signaling. Moreover, we
demonstrated that sequestration of Hb
within large protein complexes that block
the extravasation is sufﬁcient to restore
vascular NO function. The archetypical Hb
scavenger proteins Hp and PIT54 thus
represent evolutionarily independent
developments to extrapolate the protective
paradigm of Hb compartmentalization
beyond RBCs.
Our in vivo experiments in rats
suggested that Hp limits arterial blood
pressure increases during Hb infusion by
preserving NO signaling in the systemic
circulation. Although Hp only marginally
slowed the NO reaction with HbO2, it
blocked constriction of NO-dilated coronary
artery segments exposed to cell-free HbO2
ex vivo. Moreover, we found that addition of
Hp fully reversed Hb-induced vasoconstriction,
indicating that functional NO signaling can
be rapidly restored if the translocation process
of HbO2 into the vascular wall is interrupted.
In more speciﬁc in vitro experiments, we
demonstrated that Hp uncoupled the two
processes of vasodilatory NO signaling in
the vascular wall and NO consumption
by cell-free Hb in solution. We could
demonstrate that this Hp activity is solely
determined by the large molecular size of
the complex. The established antioxidant
functions of Hp may further enhance
its vasoprotective activity in certain
pathophysiologic conditions (34–36).
NO consumption by cell-free Hb has
been studied as a disease-related pathway in
patients with SCD (12, 13, 37, 38). Prior
research has indicated that chronic NO
depletion may cause pulmonary
hypertension in some patients with SCD
having more severe hemolysis, and recent
clinical data have reinforced this concept
(39, 40). Most extant studies have focused
on NO-consuming reactions of cell-free
Hb in plasma, particularly within the RBC-
free zone adjacent to the luminal surface of
the endothelium. Our data further extend
these concepts by demonstrating that
cell-free Hb can also redistribute directly
into the smooth muscle cell compartment
of the arterial wall as well as into other
extravascular spaces, such as the myocardium.
Leakage of cell-free Hb into tissue
interstitial spaces may also be a
fundamental mechanism underlying other
hemolysis-driven processes, such as Hb-
triggered tissue oxidation and inﬂammatory
signaling (37–40), which may be much
more pronounced in tissues having lower
heme- and radical-buffering capacity than
does blood.
NO consumption is also reported to
be a harmful consequence of Hb-based
oxygen carrier blood substitutes (31, 41–44).
Polymerized or conjugated Hb molecules,
with larger molecular sizes but comparable
NO and O2 reaction kinetics, were shown
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to have less pronounced vasopressor effects
(16, 45). Although extravasation of smaller
Hb compounds or Hb-based oxygen
carrier fragments has been postulated as
an explanation for these observations,
translocation of cell-free Hb into the
vascular wall has not been extensively
documented (16). This lack of evidence
may be related to methodological
difﬁculties associated with Hb tracking
in vivo. In our study, we exploited an
indirect labeling technique with small,
biochemically inert click-chemistry
tags that allowed us to track free Hb and
Hb:Hp complexes in vivo. Our ﬁndings
demonstrate that, in the absence of Hp, free
Hb extravasates into the kidneys and the
interstitial spaces of the myocardium as well
as into the muscular layer of coronary
arteries where local NO consumption would
be expected to cause vasoconstriction. In
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contrast, when Hp was available, tissue
extravasation was blocked, and Hb remained
sequestered in the vasculature. These data
were supported by the demonstration of
extravasation of untagged Hb in ex vivo
perfused porcine hearts and by the
detection of Hb by EPR in the vascular
wall. Within the concentration range of
free Hb tested in our studies, which may
represent most hemolytic conditions, the
vascular NO sparing effect of the Hb:Hp
complex was comparable to that provided
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by the compartmentalization function of
normal RBCs. Of course, it is likely that
at higher Hb concentrations approaching
the physiologic Hb concentration in blood
of 15 g/dL, other characteristics that
are unique to RBCs, such as the cell-free
zone in the periphery of the blood ﬂow,
become increasingly important (46).
Intriguingly, we found that the
evolutionarily and structurally unrelated
plasma Hb-binding protein PIT54 provided
the same mechanism for restoring vascular
NO signaling via sequestration of cell-free
Hb in a large protein complex. Given these
observations, it is likely that the harmful
effects of cell-free Hb promoted
independent evolutionary processes that
ultimately merged toward a single
mechanism, recapitulating the concept of
Hb compartmentalization within the
intravascular space. In humans, another
evolutionary event resulted in three primary
Hp phenotypes with dimeric (Hp 1-1) and
multimeric (Hp 2-1 and Hp 2-2) structure
and differing molecular weights. Studies
presented here are restricted to the
multimeric Hp phenotype. However, based
on earlier studies, in which we conﬁrmed
that monomeric and multimeric have
identical activity against Hb-triggered
hypertension, we do not assume that
this polymorphism would signiﬁcantly
affect the compartmentalization function
of Hp (24).
Compartmentalization of Hb in the Hb:
Hp complex extends the plasma half-life of
the complex in animal models compared
with free Hb because renal elimination is
blocked (34). It is therefore possible that
Hp-facilitated clearance of the Hb:Hp
complex by the scavenger receptor CD163
occurred as a secondary evolutionary
development to provide a nonrenal Hb
clearance pathway and heme-iron recovery
by macrophages (20).
In conclusion, we found that the
balance of compartmentalization and
extravascular translocation of cell-free
Hb determines deregulation of vascular
NO signaling during hemolysis. Control
of these fundamental disease-deﬁning
processes is provided by evolutionarily
redundant protection systems, which
support compartmentalization of
cell-free Hb in the intravascular space.
Supplementation of plasma-puriﬁed or
recombinant Hp, or analogous Hb
scavengers, may support vascular NO
homeostasis and prevent vascular
disease complications in patients with
hemolysis. n
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